Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial

[1]  L. Dans,et al.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. , 2013, The Cochrane database of systematic reviews.

[2]  B. Cuthbertson,et al.  Mortality and quality of life in the five years after severe sepsis , 2013, Critical Care.

[3]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[4]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[5]  A E Ades,et al.  An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. , 2012, Health technology assessment.

[6]  Andrew Thomas,et al.  The BUGS project: Evolution, critique and future directions , 2009, Statistics in medicine.

[7]  A. Delaney,et al.  Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta‐analysis * , 2007, Critical care medicine.

[8]  R. Schmieder,et al.  Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study * , 2007, Critical care medicine.

[9]  A. Nierhaus,et al.  Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock * , 2007, Critical care medicine.

[10]  M. Aalabaf-Sabaghi.  Decision modelling for health economic evaluation , 2007, Journal of Epidemiology and Community Health.

[11]  J. Rosenthal,et al.  Markov Chain Monte Carlo , 2018 .

[12]  B. Hutton,et al.  Meta-analysis: Intravenous Immunoglobulin in Critically Ill Adult Patients with Sepsis , 2007, Annals of Internal Medicine.

[13]  W. Hiddemann,et al.  IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial* , 2006, Critical care medicine.

[14]  D. Harrison,et al.  The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database , 2006, Critical care.

[15]  J. Rello,et al.  EFFECTS OF HIGH-DOSE OF INTRAVENOUS IMMUNOGLOBULIN AND ANTIBIOTICS ON SURVIVAL FOR SEVERE SEPSIS UNDERGOING SURGERY , 2005, Shock.

[16]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[17]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[18]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[19]  S. Tuğrul.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view – authors' response , 2002, Critical Care.

[20]  K. Venetsanou,et al.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view , 2002, Critical care.

[21]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .

[22]  Cam Donaldson,et al.  An economic evaluation of activated protein C treatment for severe sepsis. , 2002, The New England journal of medicine.

[23]  Y. Seyhun,et al.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830] , 2002, Critical care.

[24]  C. Formica,et al.  PID7: OBSERVATIONAL EVALUATION OF HEALTH STATE UTILITIES AMONG A COHORT OF SEPSIS PATIENTS , 2001 .

[25]  S. Saint,et al.  PID1: EFFICACY OF ZINC LOZENGES ON THE DURATION OF COMMON COLD SYMPTOMS: A META-ANALYSIS REVISITED , 2001 .

[26]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[27]  C. R. Palmer.  Encyclopedia of Biostatistics , 1999, BMJ.

[28]  K Claxton,et al.  An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.

[29]  A. Rubinstein,et al.  Treatment of septic thrombocytopenia with immune globulin , 1991, Journal of Clinical Immunology.

[30]  Andrew Briggs,et al.  Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  M. A. Best.  Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[32]  K R Abrams,et al.  Bayesian methods in meta-analysis and evidence synthesis. , 2001, Statistical methods in medical research.

[33]  L. Dans,et al.  Intravenous immunoglobulin for treating sepsis and septic shock. , 2002, The Cochrane database of systematic reviews.

[34]  L. Dominioni,et al.  High-dose intravenous IgG for treatment of severe surgical infections , 1996 .

[35]  R. Dellinger,et al.  Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. , 1993, Critical care medicine.

[36]  C. De Simone,et al.  Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. , 1988, Critical care medicine.

[37]  R. Grundmann,et al.  Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis--a prospective randomized study. , 1988, Progress in clinical and biological research.